Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. - sprookjes - yvandenbroek - TriplyDB

Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract.

Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract.

http://www.wikidata.org/entity/Q38320741

about

Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach Novel vaccine development strategies for inducing mucosal immunity Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection Enhancing the Protective Immune Response against Botulism Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model.Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins.Binding to gangliosides containing N-acetylneuraminic acid is sufficient to mediate the immunomodulatory properties of the nontoxic mucosal adjuvant LT-IIb(T13I)PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus antigens.Functional diversity of heat-labile toxins (LT) produced by enterotoxigenic Escherichia coli: differential enzymatic and immunological activities of LT1 (hLT) AND LT4 (pLT)Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations Murine Chlamydia trachomatis genital infection is unaltered by depletion of CD4+ T cells and diminished adaptive immunity.Characterization of antigen-presenting cells induced by intragastric immunization with recombinant chimeric immunogens constructed from Streptococcus mutans AgI/II and type I or type II heat-labile enterotoxins Mucosal immunization with a Staphylococcus aureus IsdA-cholera toxin A2/B chimera induces antigen-specific Th2-type responses in mice.Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants.A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking.Nasal Administration of Cholera Toxin as a Mucosal Adjuvant Damages the Olfactory System in Mice.VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells.Intranasal delivery of vaccines against HIV.Sublingual vaccination with influenza virus protects mice against lethal viral infection.Immunity to a self-derived, channel-forming peptide in the respiratory tract.Delivery systems and adjuvants for oral vaccines.Mucosal vaccine development for botulinum intoxication.Mucosal vaccine adjuvants update.Mouse models for the study of mucosal vaccination against otitis media.Mammalian cell ganglioside-binding specificities of E. coli enterotoxins LT-IIb and variant LT-IIb(T13I)Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines Nanoemulsion mucosal adjuvant uniquely activates cytokine production by nasal ciliated epithelium and induces dendritic cell trafficking.Dry influenza vaccines: towards a stable, effective and convenient alternative to conventional parenteral influenza vaccination.The immune complex CTA1-DD/IgG adjuvant specifically targets connective tissue mast cells through FcγRIIIA and augments anti-HPV immunity after nasal immunization.Enterotoxigenic Escherichia coli heat-stable toxin and heat-labile toxin toxoid fusion 3xSTaN12S-dmLT induces neutralizing anti-STa antibodies in subcutaneously immunized mice.Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge.The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT

P2860

Q24594741-509BB29E-67D3-4B9B-8A8F-F64C58B4063C Q24607533-37CEC918-C315-432E-8B30-2646735C71C8 Q27001897-0157B537-7ACF-4415-A885-5E17FD7BBCF5 Q27678122-F350AD7A-6FD0-46EB-ACB7-042A225E807E Q33359620-26AC15B9-0693-4E74-B65C-3A347FD84266 Q33584872-92D2153B-C6F8-41BE-A1CD-E4E13F2B0576 Q33676552-495151C3-8D37-4446-829B-A40D903F2FFD Q33768109-DD454246-2335-43D8-9676-0ACA5CA74137 Q33909162-9D1ADA4A-446B-4ECD-A5AC-34E2EEE68F9A Q34116871-108571A2-275A-4B20-9BBF-FD7EF324C7F5 Q34568384-28AF08A1-4586-41DB-A522-C9507F11908E Q34641666-0FC29E98-E6BF-4AC4-8A16-32F2C34BE576 Q34743290-58AE130F-6AD0-4440-BEEF-81DFA36B02DC Q34972133-2F833013-3F72-4C3B-83C3-3B52DCAA20BB Q35191220-5375557C-1F1E-44B3-9FBD-08373E634FF6 Q35689341-67E21FC2-D7A6-467D-AEF3-DA003398045D Q35747402-88CCCF50-E60B-4D40-99A7-B7835DA03D9E Q35793731-43239581-D6B7-4B58-9348-95954DA4605C Q36161076-5E58522F-EBEF-4671-B744-36E84864DB05 Q36409054-3F9370A1-4BEB-48A4-8052-FDCFEB34FCB1 Q36446440-7764B5DF-4DD1-459C-891C-FE2B12A2B472 Q36452329-9993541F-23AF-4546-B61C-756AE6841F53 Q36640326-55D93F83-58F1-437B-9F80-F4BB93AFDFFE Q36728788-2964F61E-FCD6-45E0-9A33-2E5B0B60D150 Q36758075-0877DCDF-6C6F-4686-BD97-5C9232C347F1 Q37093093-0BFCF46E-0213-4540-BC41-AEBAA52948B6 Q37433809-716BE41B-205B-4FA0-B852-F32165FA1597 Q37590337-2615D4EE-7B92-4AFD-8032-D7776FC3E920 Q37594498-95B4C7F9-1A8D-49CB-9371-E4C27914EA2E Q38818697-16D9C055-28CA-4218-A87E-B4879FEF1EB4 Q39168847-02BE0017-07B3-4E71-BE6C-96F937BA152E Q39218689-6DF5FFA6-2F04-4D31-9435-BC318F570CA9 Q43731325-BACF3983-0715-403E-9E40-F3E3A07560FB Q57945015-BF8B0E8A-9F65-4D64-BB23-90461D8A6FEE

P2860

Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract.

http://www.wikidata.org/entity/Q38320741

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Enterotoxin-based mucosal adju ...... responses in the nasal tract.

@en

type

label

Enterotoxin-based mucosal adju ...... responses in the nasal tract.

@en

prefLabel

Enterotoxin-based mucosal adju ...... responses in the nasal tract.

@en

P1433

Q38320741-689E331D-63FF-4B7A-A65A-A9CDE83A5CE0

P1476

Q38320741-C2CEFCAF-C9D4-49DF-8722-87F2F7018C55

P2093

Q38320741-012FE8BA-6BBB-4B9D-888A-63904EFC4C1C

Q38320741-387947A8-7C00-4563-9983-912D224723BE

Q38320741-49606ADD-5B82-4045-B8A3-BB00A85DBB33

Q38320741-5C52CE21-91EA-4AB4-AE61-8E83DC29EEED

Q38320741-66FAAC03-E569-478B-B398-FC40533AA9FD

Q38320741-93207DAE-6453-419D-8E2C-856CFE0D65FC

Q38320741-B842F8C8-4411-400B-8E50-1DACEE415118

Q38320741-B96F5052-5F34-4637-96B7-0E86D7A36F76

Q38320741-CB879064-4A0F-4EA8-BD02-D00854906DFE

Q38320741-F16D4CAE-88C2-436D-A59E-F1A0B812403A

P2860

Q38320741-051B4DF9-C0D1-455F-87E8-32CD283E7ABE

Q38320741-0C000C1F-21E1-4DC9-BC13-4BC76A5CF2B5

Q38320741-13CC338C-6750-4D77-B82A-FD9724CAE052

Q38320741-1457D856-C1C6-47A0-84EA-6613415411A3

Q38320741-160201AF-D58F-4F5F-A203-8F1322925D36

Q38320741-18CAE326-F03B-4B56-9F13-4231E310396D

Q38320741-1A235926-F415-47F7-AAFF-E9DF8344BB88

Q38320741-1AE264E9-EDCB-4776-9DC2-8798D72EF027

Q38320741-1D1632AC-5812-44D7-B487-4210231EE6E7

Q38320741-1EC3DFBE-A396-446D-8CBF-12D0E5E770C8

P304

Q38320741-0B1DB308-80BE-4340-95C8-D714011D1C51

P31

Q38320741-1A1F0B1A-AEE3-4B7F-828F-42E79898ADB0

P356

Q38320741-ED2E6BE1-81B5-4364-8646-F2AF081FD62D

P407

Q38320741-EAE21417-622B-44EF-8A32-07DBA666A7DD

P433

Q38320741-6C60C8D0-E461-44B0-BC6D-8773DB247F18

P478

Q38320741-AEBA8401-0D99-4E2E-A675-3E0C21DFC889

P577

Q38320741-846CF109-51A5-4692-A692-2DC3589E9C68

P698

Q38320741-244AB7D3-5E1E-45AB-A1BC-0F847415BF58

P921

Q38320741-93B4116F-D738-411D-9EF5-B0EF1EA54B2C

P932

Q38320741-6556E250-0206-47B4-A367-5D328BD69107

P356

IAI.73.10.6892-6902.2005

P1433

Infection and Immunity

P1476

Enterotoxin-based mucosal adju ...... responses in the nasal tract.

@en

P2093

Daniel J Metzger

http://www.w3.org/2001/XMLSchema#string

Frederik W van Ginkel

http://www.w3.org/2001/XMLSchema#string

Hong L Vu

http://www.w3.org/2001/XMLSchema#string

Jerry R McGhee

http://www.w3.org/2001/XMLSchema#string

Kohtaro Fujihashi

http://www.w3.org/2001/XMLSchema#string

Michael Martin

http://www.w3.org/2001/XMLSchema#string

Naoto Yoshino

http://www.w3.org/2001/XMLSchema#string

Raymond J Jackson

http://www.w3.org/2001/XMLSchema#string

Terry D Connell

http://www.w3.org/2001/XMLSchema#string

Yukari Hagiwara

http://www.w3.org/2001/XMLSchema#string

P2860

Rapid and efficient site-specific mutagenesis without phenotypic selection

Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers.

Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans

Entry of cholera toxin into polarized human intestinal epithelial cells. Identification of an early brefeldin A sensitive event required for A1-peptide generation.

Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit.

Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb

A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies.

Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants

Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina.

Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin

P304

6892-6902

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/IAI.73.10.6892-6902.2005

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16177369

http://www.w3.org/2001/XMLSchema#string

P921

P932

1230900

http://www.w3.org/2001/XMLSchema#string